Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
57.65
+0.33 (0.58%)
At close: Jul 25, 2025, 4:00 PM
57.69
+0.04 (0.07%)
After-hours: Jul 25, 2025, 7:59 PM EDT
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 11 analysts that cover Hims & Hers Health stock have a consensus rating of "Hold" and an average price target of $40.73, which forecasts a -29.35% decrease in the stock price over the next year. The lowest target is $26 and the highest is $68.
Price Target: $40.73 (-29.35%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Hims & Hers Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 7 | 6 | 7 | 7 | 7 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $45 → $48 | Hold | Maintains | $45 → $48 | -16.74% | Jul 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $40 | Hold | Reiterates | $40 | -30.62% | Jun 11, 2025 |
| Needham | Needham | Strong Buy Maintains $61 → $65 | Strong Buy | Maintains | $61 → $65 | +12.75% | Jun 4, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $35 → $39 | Hold | Reiterates | $35 → $39 | -32.35% | May 6, 2025 |
| Citigroup | Citigroup | Strong Sell Maintains $25 → $30 | Strong Sell | Maintains | $25 → $30 | -47.96% | May 6, 2025 |
Financial Forecast
Revenue This Year
2.40B
from 1.48B
Increased by 62.27%
Revenue Next Year
2.87B
from 2.40B
Increased by 19.82%
EPS This Year
0.68
from 0.53
Increased by 28.02%
EPS Next Year
0.97
from 0.68
Increased by 41.92%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5B | 3.2B | 4.1B | ||
| Avg | 2.4B | 2.9B | 3.5B | ||
| Low | 2.3B | 2.5B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 70.1% | 32.3% | 44.1% | ||
| Avg | 62.3% | 19.8% | 20.8% | ||
| Low | 52.8% | 4.2% | 3.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.02 | 1.56 | 1.92 |
| Avg | 0.68 | 0.97 | 1.29 |
| Low | 0.34 | 0.44 | 0.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 91.4% | 129.6% | 98.7% |
| Avg | 28.0% | 41.9% | 33.0% |
| Low | -35.6% | -35.3% | -5.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.